Zymeworks Inc. Common Stock
$ 24.19
0.00%
17 Jul - close price
- Market Cap 1,779,754,000 USD
- Current Price $ 24.19
- High / Low $ 24.59 / 24.01
- Stock P/E N/A
- Book Value 2.19
- EPS -1.37
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.16 %
- ROE -0.42 %
- 52 Week High 29.75
- 52 Week Low 11.51
About
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops and markets biotherapeutic products for the treatment of cancer. The company is headquartered in Vancouver, Canada.
Analyst Target Price
$39.33
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-03-02 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-03-05 | 2024-10-31 | 2024-08-01 | 2024-05-02 | 2024-03-06 | 2023-11-07 | 2023-08-10 |
| Reported EPS | -0.59 | -0.55 | -0.26 | 0.03 | -0.3 | -0.31 | -0.39 | -0.49 | -0.42 | -0.2 | -0.41 | -0.76 |
| Estimated EPS | -0.1 | -0.3224 | -0.32 | -0.52 | -0.7 | -0.0922 | -0.41 | -0.31 | -0.29 | -0.43 | -0.47 | -0.47 |
| Surprise | -0.49 | -0.2276 | 0.06 | 0.55 | 0.4 | -0.2178 | 0.02 | -0.18 | -0.13 | 0.23 | 0.06 | -0.29 |
| Surprise Percentage | -490% | -70.5955% | 18.75% | 105.7692% | 57.1429% | -236.2256% | 4.878% | -58.0645% | -44.8276% | 53.4884% | 12.766% | -61.7021% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.39 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ZYME
2026-07-03 21:40:27
Irish law firm Arthur Cox advised Theravance Biopharma on its acquisition by biotechnology company Zymeworks Inc. The deal, valued at $929 million in equity, will see Theravance Biopharma shareholders receive cash and a contingent value right for future proceeds. This transaction follows a strategic review and aims to maximize shareholder value.
2026-06-30 08:09:42
Zymeworks Inc. is acquiring Dublin-based Theravance Biopharma Inc. for US$929-million in cash, financed partly by Zymeworks' own funds and partly by the Ontario Municipal Employees Retirement System (OMERS). This acquisition marks Zymeworks' entry into the respiratory illness market, leveraging Theravance's COPD drug Yupelri and potentially benefiting from sales of another respiratory drug, Trelegy Ellipta. The deal follows Zymeworks' shift to a royalty-based business model and is structured to avoid shareholder dilution.
2026-06-29 19:40:26
Vancouver-based Zymeworks Inc. is acquiring California's Theravance Biopharma Inc. for US$929 million in cash, a move that diversifies Zymeworks' drug portfolio beyond oncology into respiratory-disease treatments. This acquisition follows Theravance's disappointing clinical trial results and subsequent restructuring. Zymeworks CEO Kenneth Galbraith stated this acquisition aligns with his strategy to build a more diversified and durable business by integrating partner-driven cash flows and innovative R&D.
2026-06-20 09:11:35
Gandeeva Therapeutics and Zymeworks Inc. have announced a collaboration to use Gandeeva's cryo-electron microscopy (cryo-EM) platform to accelerate antibody drug discovery. This partnership aims to leverage cryo-EM technology to gain deeper structural insights into therapeutic antibodies, thereby streamlining the development process for novel treatments. The collaboration signifies a move towards more advanced and efficient methods in biopharmaceutical research and development.
2026-06-19 03:39:26
Gandeeva Therapeutics and Zymeworks have partnered to use cryo-electron microscopy (cryo-EM) to generate structural data for accelerating antibody drug discovery. Gandeeva scientists successfully determined the structure of a small and flexible antigen bound to a Zymeworks antibody fragment, visualizing the antibody-binding epitope at high resolution. This breakthrough provides crucial insights for selecting and optimizing antibody leads, particularly for AI-driven antibody design.
2026-06-19 03:09:55
Gandeeva Therapeutics and Zymeworks have partnered to enhance antibody drug discovery using cryo-electron microscopy (cryo-EM). Their collaboration successfully visualized a small, flexible antigen bound to an antibody Fab fragment at high resolution, providing crucial insights for optimizing biologics. This advancement is expected to accelerate the design of AI-driven antibodies and improve the development of precision medicines.
